PTC Therapeutics PTCT Noncash Interest Expense Liability Related To Sale Of Future Royalties
Noncash Interest Expense Liability Related To Sale Of Future Royalties at other companies
Other financials
Where this comes from
Reported directly by PTC Therapeutics in its filing.
Tagged under the XBRL concept ptct:NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties.
The official record: PTC Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about PTC Therapeutics's noncash interest expense liability related to sale of future royalties.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is PTC Therapeutics's noncash interest expense liability related to sale of future royalties?
- PTC Therapeutics (PTCT) reported noncash interest expense liability related to sale of future royalties of $65.7M in Q1 2026.
- How has PTC Therapeutics's noncash interest expense liability related to sale of future royalties changed year-over-year?
- PTC Therapeutics's noncash interest expense liability related to sale of future royalties increased by 32.3% year-over-year, from $49.66M to $65.7M.
- What is the long-term trend for PTC Therapeutics's noncash interest expense liability related to sale of future royalties?
- Over 4 years (2021 to 2025), PTC Therapeutics's noncash interest expense liability related to sale of future royalties has grown at a 29.0% compound annual growth rate (CAGR), from $77.68M to $215.16M.
- What does noncash interest expense liability related to sale of future royalties mean?
- Reflects the non-cash interest expense accrued on liabilities associated with the sale of future royalty rights. It accounts for the effective interest rate applied to the financing obligation over the life of the royalty agreement.